drugset / Trial / NCT02292459

Efficacy and Safety of Polyethylene Glycol 3350 (PEG 3350) for Relief of Constipation (MK-8114-005)

NCT02292459

Phase 3 Withdrawn Bayer
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the complete resolution of constipation in participants taking PEG 3350 compared to those taking PEG 4000, based on analysis of the number of bowel movements from self-reported bowel movement (BM) data. The complete resolution of constipation is defined as the elimination of straining or of hard/lumpy stools.

Timeline

Start
2015-12
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator PEG 4000 Unknown 10 g Oral
Comparator PEG 4000 Unknown 20 g Oral
Subject polyethylene glycol Other / unclassified 17 g Oral

Indications